BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22156453)

  • 1. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
    Weinreb O; Amit T; Mandel S; Youdim MB
    Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Bar-Am O; Youdim MB
    Neuroscience; 2011 Aug; 189():345-58. PubMed ID: 21570450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
    Weinreb O; Amit T; Mandel S; Kupershmidt L; Youdim MB
    Antioxid Redox Signal; 2010 Sep; 13(6):919-49. PubMed ID: 20095867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Carri MT; Youdim MB
    FASEB J; 2009 Nov; 23(11):3766-79. PubMed ID: 19638399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
    Mandel SA; Avramovich-Tirosh Y; Reznichenko L; Zheng H; Weinreb O; Amit T; Youdim MB
    Neurosignals; 2005; 14(1-2):46-60. PubMed ID: 15956814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Youdim MB; Geldenhuys WJ; Van der Schyf CJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential application of iron chelators for the treatment of neurodegenerative diseases.
    Hider RC; Roy S; Ma YM; Le Kong X; Preston J
    Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
    Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
    FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease.
    Salkovic-Petrisic M; Knezovic A; Osmanovic-Barilar J; Smailovic U; Trkulja V; Riederer P; Amit T; Mandel S; Youdim MB
    Life Sci; 2015 Sep; 136():108-19. PubMed ID: 26159898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities.
    Merelli A; Rodríguez JCG; Folch J; Regueiro MR; Camins A; Lazarowski A
    Curr Neuropharmacol; 2018; 16(10):1484-1498. PubMed ID: 29318974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation and neuroprotection in neurodegenerative diseases.
    Li X; Jankovic J; Le W
    J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia inducible factor-1 as a target for neurodegenerative diseases.
    Zhang Z; Yan J; Chang Y; ShiDu Yan S; Shi H
    Curr Med Chem; 2011; 18(28):4335-43. PubMed ID: 21861815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.